KDMN Stock - Kadmon Holdings, Inc.
Unlock GoAI Insights for KDMN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $8.29M | $5.09M | $1.40M | $12.26M | $26.05M |
| Gross Profit | $6.29M | $3.81M | $714,000 | $9.28M | $22.18M |
| Gross Margin | 75.9% | 74.7% | 51.1% | 75.7% | 85.1% |
| Operating Income | $-102,281,000 | $-89,080,000 | $-85,896,000 | $-68,556,000 | $-119,535,000 |
| Net Income | $-108,913,000 | $-61,368,000 | $-54,252,000 | $-79,774,000 | $-208,755,000 |
| Net Margin | -1314.1% | -1204.5% | -3886.2% | -650.5% | -801.2% |
| EPS | $-0.66 | $-0.46 | $-0.56 | $-1.39 | $-8.82 |
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Visit WebsiteEarnings History & Surprises
KDMNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2021 | Nov 4, 2021 | $-0.20 | $-0.20 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $-0.18 | $-0.18 | 0.0% | = MET |
Q2 2021 | May 6, 2021 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q1 2021 | Mar 4, 2021 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q2 2020 | May 7, 2020 | $-0.14 | $-0.19 | -35.7% | ✗ MISS |
Q1 2020 | Mar 5, 2020 | $-0.21 | $-0.09 | +57.1% | ✓ BEAT |
Q4 2019 | Nov 7, 2019 | $-0.22 | $-0.49 | -122.7% | ✗ MISS |
Q3 2019 | Aug 5, 2019 | $-0.16 | $0.07 | +143.8% | ✓ BEAT |
Q2 2019 | May 9, 2019 | $-0.16 | $0.02 | +112.5% | ✓ BEAT |
Q1 2019 | Mar 7, 2019 | $-0.19 | $-0.37 | -94.7% | ✗ MISS |
Q4 2018 | Nov 9, 2018 | $-0.23 | $-0.13 | +43.5% | ✓ BEAT |
Q3 2018 | Aug 9, 2018 | $-0.26 | $0.24 | +192.3% | ✓ BEAT |
Q2 2018 | May 8, 2018 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q1 2018 | Mar 6, 2018 | $-0.36 | $-0.24 | +33.3% | ✓ BEAT |
Q4 2017 | Nov 9, 2017 | $-0.39 | $-0.42 | -7.7% | ✗ MISS |
Q3 2017 | Aug 3, 2017 | $-0.49 | $-0.44 | +10.2% | ✓ BEAT |
Q2 2017 | May 15, 2017 | $-0.52 | $-0.39 | +25.0% | ✓ BEAT |
Q1 2017 | Mar 22, 2017 | $-1.15 | $-0.50 | +56.5% | ✓ BEAT |
Latest News
Frequently Asked Questions about KDMN
What is KDMN's current stock price?
What is the analyst price target for KDMN?
What sector is Kadmon Holdings, Inc. in?
What is KDMN's market cap?
Does KDMN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to KDMN for comparison